PepGen (PEPG) Research & Development (2021 - 2026)
PepGen (PEPG) posted Research & Development of $13.0 million for Q1 2026, down 6.12% sequentially from $13.9 million in Q4 2025, and down 48.76% YoY from $25.4 million in Q1 2025.
PepGen (PEPG) Research & Development (2021 - 2026) Analysis & Trends
PepGen has reported Research & Development for 6 years, with the latest figure at $13.0 million in Q1 2026.
- Quarterly Research & Development fell 48.76% year-over-year to $13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.7 million (down 32.66% YoY) and the FY2025 annual result came in at $71.0 million, down 7.11% from the prior year.
- Research & Development retreated to $13.0 million in Q1 2026 per PEPG's latest filing, from $13.9 million in the prior quarter.
- Over five years, Research & Development peaked at $25.4 million in Q1 2025 and troughed at $10.7 million in Q1 2022.
- A 5-year average of $16.6 million and a median of $16.0 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2026: Research & Development jumped 342.79% in 2022, then sank 48.76% in 2026.
- Over 5 years, Research & Development stood at $13.2 million in 2022, then advanced by 23.8% to $16.3 million in 2023, then climbed by 16.33% to $19.0 million in 2024, then dropped by 26.95% to $13.9 million in 2025, then fell by 6.12% to $13.0 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $13.0 million, $13.9 million, and $13.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | PepGen | 207.09 Mn | 207.09 Mn | - | 12.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.52 Mn |
| Mar 31, 2026 | 13.00 Mn |
| Dec 31, 2025 | 13.85 Mn |
| Sep 30, 2025 | 13.42 Mn |
| Jun 30, 2025 | 18.39 Mn |
| Mar 31, 2025 | 25.38 Mn |
| Dec 31, 2024 | 18.96 Mn |
| Sep 30, 2024 | 17.72 Mn |
| Jun 30, 2024 | 25.06 Mn |
| Mar 31, 2024 | 14.73 Mn |
| Dec 31, 2023 | 16.30 Mn |
| Sep 30, 2023 | 20.54 Mn |
| Jun 30, 2023 | 16.93 Mn |
| Mar 31, 2023 | 14.36 Mn |
| Dec 31, 2022 | 13.17 Mn |
| Sep 30, 2022 | 15.96 Mn |
| Jun 30, 2022 | 14.24 Mn |
| Mar 31, 2022 | 10.71 Mn |
| Dec 31, 2021 | 4.54 Mn |
| Sep 30, 2021 | 5.71 Mn |